- Home
- CAPR vs EFR Comparison
CAPR vs EFR Comparison
Compare CAPR & EFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAPR
- EFR
- Stock Information
- Founded
- CAPR 2005
- EFR 2003
- Country
- CAPR United States
- EFR United States
- Employees
- CAPR N/A
- EFR N/A
- Industry
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- EFR Trusts Except Educational Religious and Charitable
- Sector
- CAPR Health Care
- EFR Finance
- Exchange
- CAPR Nasdaq
- EFR Nasdaq
- Market Cap
- CAPR 324.6M
- EFR 342.8M
- IPO Year
- CAPR N/A
- EFR N/A
- Fundamental
- Price
- CAPR $6.92
- EFR $11.36
- Analyst Decision
- CAPR Strong Buy
- EFR
- Analyst Count
- CAPR 6
- EFR 0
- Target Price
- CAPR $23.00
- EFR N/A
- AVG Volume (30 Days)
- CAPR 1.1M
- EFR 88.6K
- Earning Date
- CAPR 11-11-2025
- EFR 01-01-0001
- Dividend Yield
- CAPR N/A
- EFR 9.43%
- EPS Growth
- CAPR N/A
- EFR N/A
- EPS
- CAPR N/A
- EFR 1.69
- Revenue
- CAPR $13,392,150.00
- EFR N/A
- Revenue This Year
- CAPR N/A
- EFR N/A
- Revenue Next Year
- CAPR $7,894.07
- EFR N/A
- P/E Ratio
- CAPR N/A
- EFR $7.74
- Revenue Growth
- CAPR N/A
- EFR N/A
- 52 Week Low
- CAPR $5.68
- EFR $10.95
- 52 Week High
- CAPR $22.90
- EFR $13.29
- Technical
- Relative Strength Index (RSI)
- CAPR 53.74
- EFR 50.11
- Support Level
- CAPR $6.05
- EFR $11.26
- Resistance Level
- CAPR $6.42
- EFR $11.49
- Average True Range (ATR)
- CAPR 0.39
- EFR 0.10
- MACD
- CAPR -0.01
- EFR 0.02
- Stochastic Oscillator
- CAPR 56.28
- EFR 66.67
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
About EFR Eaton Vance Senior Floating-Rate Fund of Beneficial Interest
Eaton Vance Senior Floating Rate Trust is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income. As a secondary objective, the fund intends to seek capital preservation. Its portfolio of investments consists of Software, Health Care Providers & Services, Machinery, Chemicals, Professional Services, IT Services, Hotels, Restaurants & Leisure, Capital Markets, Specialty Retail, Commercial Services & Supplies, and other areas. The trust invests in below investment grade floating rate loans, which are considered speculative because of the credit risk of their issuers.